The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under
development for the treatment of type 2 diabetes (T2D) and obesity. Its association with …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …